Patents by Inventor Boh Chang Lin

Boh Chang Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11000585
    Abstract: The majority of the mortality observed in young pigs occurs between three and five weeks post-weaning for S. suis infections and between four and six weeks post-weaning for H. parasuis and Actinobacillus suis infections. Clinical disease control associated with S. suis, A. suis and H. parasuis has been attempted using antibiotic treatment, by controlled exposure with live organisms, and by vaccination, using either inactivated commercial or autogenous bacterins administered parenterally. A similar lack of protection in very young pigs is observed with various viruses including swine influenza virus, porcine reproductive and respiratory syndrome virus, porcine epidemic diarrhea virus and rotavirus. Disclosed herein is an immunogenic composition comprising inactivated antigens and a mucosal adjuvant.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: May 11, 2021
    Assignee: Phibro Animal Health Corporation
    Inventors: Grant Weaver, Jeffrey Alan Kula, Boh Chang Lin, Karen Brown, Wesley W. Johnson, Michael Dennis Murphy
  • Patent number: 10918711
    Abstract: The majority of the mortality observed in young pigs occurs between three and five weeks post-weaning for S. suis infections and between four and six weeks post-weaning for H. parasuis and Actinobacillus suis infections. Clinical disease control associated with S. suis, A. suis and H. parasuis has been attempted using antibiotic treatment, by controlled exposure with live organisms, and by vaccination, using either inactivated commercial or autogenous bacterins administered parenterally. A similar lack of protection in very young pigs is observed with various viruses including swine influenza virus, porcine reproductive and respiratory syndrome virus, porcine epidemic diarrhea virus and rotavirus. Disclosed herein is an immunogenic composition comprising inactivated antigens and a mucosal adjuvant.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: February 16, 2021
    Assignee: Phibro Animal Health Corporation
    Inventors: Grant Weaver, Jeffrey Alan Kula, Boh Chang Lin, Karen Brown, Wesley W. Johnson, Michael Dennis Murphy
  • Publication number: 20190247490
    Abstract: The majority of the mortality observed in young pigs occurs between three and five weeks post-weaning for S. suis infections and between four and six weeks post-weaning for H. parasuis and Actinobacillus suis infections. Clinical disease control associated with S. suis, A. suis and H. parasuis has been attempted using antibiotic treatment, by controlled exposure with live organisms, and by vaccination, using either inactivated commercial or autogenous bacterins administered parenterally. A similar lack of protection in very young pigs is observed with various viruses including swine influenza virus, porcine reproductive and respiratory syndrome virus, porcine epidemic diarrhea virus and rotavirus. Disclosed herein is an immunogenic composition comprising inactivated antigens and a mucosal adjuvant.
    Type: Application
    Filed: April 17, 2019
    Publication date: August 15, 2019
    Applicant: Phibro Animal Health Corporation
    Inventors: Grant Weaver, Jeffrey Alan Kula, Boh Chang Lin, Karen Brown, Wesley W. Johnson, Michael Dennis Murphy
  • Publication number: 20190231864
    Abstract: The majority of the mortality observed in young pigs occurs between three and five weeks post-weaning for S. suis infections and between four and six weeks post-weaning for H. parasuis and Actinobacillus suis infections. Clinical disease control associated with S. suis, A. suis and H. parasuis has been attempted using antibiotic treatment, by controlled exposure with live organisms, and by vaccination, using either inactivated commercial or autogenous bacterins administered parenterally. A similar lack of protection in very young pigs is observed with various viruses including swine influenza virus, porcine reproductive and respiratory syndrome virus, porcine epidemic diarrhea virus and rotavirus. Disclosed herein is an immunogenic composition comprising inactivated antigens and a mucosal adjuvant.
    Type: Application
    Filed: March 14, 2019
    Publication date: August 1, 2019
    Applicant: Phibro Animal Health Corporation
    Inventors: Grant Weaver, Jeffrey Alan Kula, Boh Chang Lin, Karen Brown, Wesley W. Johnson, Michael Dennis Murphy
  • Patent number: 10279031
    Abstract: The majority of the mortality observed in young pigs occurs between three and five weeks post-weaning for S. suis infections and between four and six weeks post-weaning for H. parasuis and Actinobacillus suis infections. Clinical disease control associated with S. suis, A. suis and H. parasuis has been attempted using antibiotic treatment, by controlled exposure with live organisms, and by vaccination, using either inactivated commercial or autogenous bacterins administered parenterally. A similar lack of protection in very young pigs is observed with various viruses including swine influenza virus, porcine reproductive and respiratory syndrome virus, porcine epidemic diarrhea virus and rotavirus. Disclosed herein is an immunogenic composition comprising inactivated antigens and a mucosal adjuvant.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: May 7, 2019
    Assignee: Phibro Animal Health Corporation
    Inventors: Grant Weaver, Jeffrey Alan Kula, Boh Chang Lin, Karen Brown, Wesley W. Johnson, Michael Dennis Murphy
  • Publication number: 20170326226
    Abstract: The majority of the mortality observed in young pigs occurs between three and five weeks post-weaning for S. suis infections and between four and six weeks post-weaning for H. parasuis and Actinobacillus suis infections. Clinical disease control associated with S. suis, A. suis and H. parasuis has been attempted using antibiotic treatment, by controlled exposure with live organisms, and by vaccination, using either inactivated commercial or autogenous bacterins administered parenterally. A similar lack of protection in very young pigs is observed with various viruses including swine influenza virus, porcine reproductive and respiratory syndrome virus, porcine epidemic diarrhea virus and rotavirus. Disclosed herein is an immunogenic composition comprising inactivated antigens and a mucosal adjuvant.
    Type: Application
    Filed: May 11, 2017
    Publication date: November 16, 2017
    Applicant: Phibro Animal Health Corporation
    Inventors: Grant Weaver, Jeffrey Alan Kula, Boh Chang Lin, Karen Brown, Wesley W. Johnson, Michael Dennis Murphy